Statins, a group of medications known for their ability to lower cholesterol levels, have been a cornerstone in preventing heart disease.
In a groundbreaking study, researchers from the University of Manchester, Manchester University NHS Foundation Trust (MFT), and Keele University have identified the most effective statins for lowering all types of “bad” cholesterol and reducing the risk of cardiovascular disease in individuals with diabetes.
This research, funded by the National Institute for Health Research (NIHR), aligns with updated guidelines from the National Institute for Health and Care Excellence (NICE).
Understanding Cholesterol and Diabetes:
High levels of “bad” cholesterol, particularly non-high-density lipoprotein cholesterol (non-HDL-C), can accumulate within blood vessel walls, increasing the risk of dangerous blood clots.
Individuals with diabetes are already at a higher risk of cardiovascular disease.
The Study’s Purpose
This study aimed to determine which of the seven commonly used statins are most effective at lowering non-HDL-C levels, a powerful predictor of cardiovascular disease risk.
While researchers already knew which statins reduced low-density lipoprotein cholesterol (LDL-C), they were unsure about which ones effectively lowered non-HDL-C, which accounts for LDL-C and other types of bad cholesterol.
Non-HDL-C has become the primary focus for reducing cardiovascular risk through cholesterol-lowering treatments. Doctors can easily calculate non-HDL-C by subtracting “good” cholesterol (HDL-C) levels from total cholesterol levels.
Key Findings
Most Effective Statins: The study revealed that rosuvastatin at moderate and high doses, as well as simvastatin and atorvastatin at high doses, were the most effective in lowering non-HDL-C levels in patients with diabetes.
These drugs led to reductions of approximately 2.20 to 2.31 millimoles per liter (mmol/l) in non-HDL-C over 12 weeks.
High-Risk Patients: Among patients at high risk of major adverse cardiac events, atorvastatin at high doses proved to be the most effective in reducing non-HDL-C by around 2.0 mmol/l.
Supporting NICE Guidelines:
The study findings align with updated NICE guidelines, which recommend using non-HDL-C, rather than LDL-C, as a better measure of cardiovascular disease risk reduction when using cholesterol-lowering treatments.
While NICE does not specifically endorse these three statins, the analysis provides valuable insights by ranking the statins that are most effective at lowering all types of bad cholesterol using non-HDL-C as the preferred target.
Conclusion
For individuals with type 2 diabetes, who are at an increased risk of cardiovascular disease, statins are crucial for preventing heart-related issues.
This study suggests that clinicians should consider using non-HDL-C as a primary measure of cardiovascular risk, as it is simple to calculate and adds minimal workload.
The three most effective statins for lowering all types of bad cholesterol, as determined by this research—rosuvastatin, simvastatin, and atorvastatin—can guide clinicians in making informed decisions about statin selection and dosages, supporting clinical judgments when balancing benefits and potential risks.
These findings provide valuable guidance for individuals with diabetes and their healthcare providers, aiming to improve cardiovascular health and reduce the risk of heart disease.
If you care about diabetes, please read studies that not all whole grain foods could benefit people with type 2 diabetes, and green tea could help reduce death risk in type 2 diabetes.
For more information about diabetes, please see recent studies about unhealthy plant-based diets linked to metabolic syndrome, and results showing Mediterranean diet could help reduce the diabetes risk by one third.
The research findings can be found in BMJ.
Follow us on Twitter for more articles about this topic.
Copyright © 2023 Knowridge Science Report. All rights reserved.
